Coronavirus Scientific Resources
Resources to educate and collaborate on COVID-19 responses
In confronting this crisis, we believe that science will win. Be sure to keep up with all of our important updates surrounding COVID-19, including press releases, supply updates and more.
Featured Coronavirus Publication
A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
APPLYING OUR SCIENTIFIC EFFORTS TO ADDRESS THE EPIDEMIC
Antiviral Efforts -
Advancing our protease inhibitors:
- (Press statement) - Pfizer Shares Pre-Clinical Data Updates on COVID-19 Antiviral Research Program
- (Pre-print manuscript - Currently undergoing scientific peer review for potential publication) - The Discovery of Ketone-Based, Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
- Data Files: SARS-CoV-1 3CL protease inhibition data on 76 compounds and their molecular structures [from patent WO2005113580]
- (Fact sheet) - Pfizer COVID-19 Response: Protease inhibitor (PDF)
- (Press release) - Pfizer Advances Battle Against COVID-19 on Multiple Fronts
- (Featured article) - All Hands on Deck as Scientists Revive SARS Protease Inhibitor to Attempt to Fight COVID-19
Vaccine Efforts -
Potentially preventing infections using mRNA vaccines:
Anti-infective Efforts -
Sharing azithromycin data:
In an effort to share information that could benefit COVID-19 mitigation efforts, Pfizer researchers published a review in Clinical Pharmacology and Therapeutics which assesses published in vitro and clinical data regarding azithromycin as an agent with antiviral properties. This open access review may serve to facilitate the use of azithromycin in future research on COVID-19. Azithromycin is not approved for the treatment of viral infections.
Research that may inform future vaccination guidelines
Pfizer Inc. and the Liverpool School of Tropical Medicine’s Respiratory Infection Clinical Research Group launched two new studies to provide insights on the interaction between S. pneumoniae and SARS-CoV-2. Pfizer's collaboration agreement with Liverpool provides funding and in-kind laboratory testing support for this research.
Collaborating to address COVID-19
As outlined in Pfizer’s five-point plan, the company has been collaborating across the healthcare innovation ecosystem ranging from large pharmaceutical companies to the smallest of biotech companies, from government agencies to academic institutions to address the COVID-19 global health care crisis.
If you’re a researcher interested in collaborating,?contact [email protected]
